Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer
Immunotherapy Index appreciated 28.0% during the first quarter of 2013. The
equally weighted Cancer Immunotherapy Index is regularly benchmarked against
the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech
Indices. For the first quarter the biotech indices averaged a 15.2% gain. 



Immunocellular Therapeutics (43%), Advaxis (197%) and Celldex (73%) have led
the sector in gains during the January thru March 2013 period. Dendreon ($731
Million), Celldex ($718 Million) and Vical ($343 Million) represent 62% of the market
capitalization of the fifteen member Cancer Immunotherapy Index which has a
combined total share value of $2.9 Billion. 



The Mentor Capital Cancer Immunotherapy Index companies and their performance
for the first thirteen weeks of 2013 follow: Galena Biopharma Corporation +37.25%,
NewLink Genetics Corporation -1.84%,  Vical Incorporated +36.77%,  Inovio Pharmaceuticals, Inc. +19.12%, Dendreon
(NASDAQ:DNDN) -10.49%, Immunocellular Therapeutics, Ltd. (NYSE MKT:IMUC) +42.71%,
 Agenus (NASDAQ:AGEN) -5.12%,  Oncothyreon (NASDAQ:ONTY) +8.07%, Biovest
International (Pink Sheets:BVTIQ) -8.80%, Celldex Therapeutics (NASDAQ:CLDX) +72.58%,
Northwest Biotherapeutics (NASDAQ:NWBO) +18.60%, CEL – SCI Corp. (NYSE MKT:CVM)
-14.44% , Generex Biotechnology (OTCBB:GNBT) +24.00% as a proxy for its
wholly-owned immunotherapeutic subsidiary, Antigen Express, Provectus Pharmaceuticals,
Inc. (Pink Sheets:PVCT) +30.36% and Advaxis, Inc. (OTCBB:ADXS) +196.67%  -  all
for an average 2013 YTD gain of +27.97%.  (Annualized rate: 112.20%).



Mentor Capital, Inc., by acquisition or stock purchase, seeks
to invest in leading-edge private and public cancer companies, and certain other
situations. Mentor created the Cancer Immunotherapy Index July 10, 2009.  Since then, it has invested or maintained a
tracking position in all companies in the Cancer Immunotherapy Index which can
be found at  www.MentorCapital.com.   



Forward Looking Statements, Safe Harbor and Risk
Descriptions are Incorporated by Reference from the MNTR Company Web Site
above.





For further information contact:



 



Chester Billingsley, CEO                   



Mentor Capital, Inc.



(760) 788 - 4700 


Mentor Capital (QB) (USOTC:MNTR)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024 Plus de graphiques de la Bourse Mentor Capital (QB)
Mentor Capital (QB) (USOTC:MNTR)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024 Plus de graphiques de la Bourse Mentor Capital (QB)